HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P Quaglino Selected Research

Erythema Multiforme

5/2008Expression of matrix metalloproteinases 2, 9 and 11 in erythema multiforme: immunohistochemical comparison with Stevens-Johnson syndrome/toxic epidermal necrolysis.
1/2008Serum interleukin-13 levels are increased in patients with Stevens-Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme.
7/2007Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.
10/2006Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.
5/2006Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
2/2006The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


P Quaglino Research Topics

Disease

18Melanoma (Melanoma, Malignant)
01/2021 - 01/2000
8Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
05/2018 - 01/2001
7Mycosis Fungoides
11/2021 - 02/2004
7Neoplasms (Cancer)
10/2021 - 01/2000
6Psoriasis (Pustulosis Palmaris et Plantaris)
03/2022 - 01/2009
6Erythema Multiforme
05/2008 - 02/2006
6Stevens-Johnson Syndrome (Lyell's Syndrome)
05/2008 - 02/2006
5Neoplasm Metastasis (Metastasis)
10/2022 - 02/2008
5Skin Diseases (Skin Disease)
10/2017 - 12/2012
5Disease Progression
06/2014 - 08/2002
3Bullous Pemphigoid (Pemphigoid)
01/2022 - 10/2012
3Necrosis
01/2011 - 10/2006
2Atopic Dermatitis (Atopic Eczema)
10/2021 - 08/2020
2Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2014 - 04/2013
2Exfoliative Dermatitis (Erythroderma)
12/2012 - 12/2012
2Ascites
01/2005 - 01/2005
2Pericardial Effusion
01/2005 - 01/2005
2Pleural Effusion (Pleural Effusions)
01/2005 - 01/2005
1Breast Neoplasms (Breast Cancer)
10/2022
1Pemphigus (Pemphigus Vulgaris)
01/2022
1Hidradenitis Suppurativa
07/2021
1Vitiligo
01/2021
1COVID-19
12/2020
1Skin Neoplasms (Skin Cancer)
10/2020
1Telangiectasis (Telangiectasia)
04/2019
1Purpura
04/2019
1Livedo Reticularis
04/2019
1Cutaneous Lupus Erythematosus
04/2019
1Lymphoma (Lymphomas)
05/2018
1Keratoacanthoma
09/2016
1Asthenia
07/2016
1Thrombocytopenia (Thrombopenia)
07/2016
1Vomiting
07/2016
1Pruritus (Itching)
07/2016
1Lethargy
07/2016
1Fever (Fevers)
07/2016
1Hypertension (High Blood Pressure)
07/2016
1Chills
07/2016
1Nausea
07/2016
1Oral Lichen Planus
06/2015
1Pain (Aches)
06/2015
1Vasculitis (Vasculitides)
04/2015
1Sunburn
01/2015
1Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)
10/2014
1Pyoderma Gangrenosum
10/2014
1Inflammation (Inflammations)
10/2014
1Systemic Scleroderma (Systemic Sclerosis)
01/2014

Drug/Important Bio-Agent (IBA)

7Messenger RNA (mRNA)IBA
01/2011 - 12/2000
6Biological ProductsIBA
05/2018 - 01/2005
6Monophenol Monooxygenase (Tyrosinase)IBA
02/2008 - 12/2000
5Pharmaceutical PreparationsIBA
03/2022 - 07/2007
5AntibodiesIBA
04/2019 - 01/2002
5CytokinesIBA
10/2014 - 02/2000
3secukinumabIBA
03/2022 - 07/2021
3CD40 Ligand (CD40L)IBA
10/2014 - 02/2006
2ixekizumabIBA
03/2022 - 01/2022
2dupilumabIBA
10/2021 - 08/2020
2AutoantibodiesIBA
04/2019 - 10/2014
2Bleomycin (Blenoxane)FDA LinkGeneric
07/2018 - 08/2008
2Interleukin-2 (IL2)IBA
09/2015 - 02/2000
2Biomarkers (Surrogate Marker)IBA
09/2015 - 06/2014
2IpilimumabIBA
09/2015 - 04/2014
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2015 - 08/2002
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
12/2012 - 09/2005
2InterleukinsIBA
10/2006 - 02/2000
2MART-1 AntigenIBA
01/2005 - 01/2005
1Aromatase InhibitorsIBA
10/2022
1COVID-19 VaccinesIBA
01/2022
1mogamulizumabIBA
11/2021
1VorinostatFDA Link
11/2021
1Brentuximab VedotinIBA
11/2021
1Immune Checkpoint InhibitorsIBA
01/2021
1PesticidesIBA
04/2020
1Bexarotene (LGD1069)FDA Link
10/2019
1anti-dsDNA autoantibodyIBA
04/2019
1Nuclear Antigens (Extractable Nuclear Antigens)IBA
04/2019
1Dihydrotachysterol (AT 10)IBA
12/2016
1quisinostatIBA
07/2016
1Histone Deacetylase InhibitorsIBA
07/2016
1Interleukin-6 (Interleukin 6)IBA
09/2015
1lactate dehydrogenase C4IBA
09/2015
1Alkaline PhosphataseIBA
09/2015
1Transaminases (Aminotransferases)IBA
09/2015
1Oxidoreductases (Dehydrogenase)IBA
09/2015
1Proteins (Proteins, Gene)FDA Link
09/2015
1ORALIT (ORS)IBA
07/2015
1Tacrolimus (Prograf)FDA LinkGeneric
06/2015
1Sunscreening Agents (Sunscreens)IBA
01/2015
1ChemokinesIBA
10/2014
1Fas Ligand Protein (Fas Ligand)IBA
10/2014
1NucleotidesIBA
06/2014

Therapy/Procedure

15Therapeutics
10/2022 - 07/2005
4Photopheresis
01/2014 - 01/2001
2Biological Therapy
12/2020 - 01/2009
2Secondary Prevention
10/2020 - 02/2012
2Bone Marrow Transplantation (Transplantation, Bone Marrow)
01/2014 - 10/2013
1Investigational Therapies (Experimental Therapy)
10/2020
1Phototherapy (Light Therapy)
05/2018
1Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
01/2017
1Retreatment
04/2014